Evidence and its Limits
The evidence on evidence-based medicine speaks for itself. The approach is a vast improvement over everything that came before, and over current rival approaches. It’s often enough to give its practitioners a bit of hubris –which is why it’s so…
It’s About the Patient
An FDA advisory committee this week gave a half-hearted vote of approval – 9-8, with two abstentions – for Alexza Pharmaceuticals Inc.’s Adasuve (Staccato loxapine). But the vote was conditioned on limiting the inhaled antipsychotic to one dose per day…
BioWorld’s Fifth Annual Biotech Holiday Gift Guide
While all you biotechs out there scramble to meet your end-of-year milestones, BioWorld would like to announce a little milestone of our own. That’s right, this is our fifth annual biotech holiday gift guide.
Can Other Cell Therapy Firms Avoid Dendreon’s Fate?
Stem cell therapies may be relatively early stage, but that hasn’t stopped their developers from giving some serious thought to late stage issues like reimbursement and health economics.
Burzynski Institute: Patient Exploitation in the Name of Research
A cursory glance at the website of the Burzynski Research Institute Inc. turns up nothing unusual. The website showcases smiling patients and its shiny, mirror-windowed building. There’s a contact number for patients to call and a prominent “Donate” button, implying…
Send Me an Angel: More VC Alternatives on the Rise
It seems to me that an increasing number of start-ups have been boot-strapping their way through preclinical without venture capital lately.
The Small IPO: Not Dead Yet? Regulation A Debated
The biotech industry has long known it’s getting harder and harder for a small company to go public.
The Biotech Toddler Argument: “Chilling Effect on Innovation” Overplayed?
In last week’s issue of BioWorld Insight, our esteemed Washington editor Mari Serebrov wrote an article titled, “Shorter Exclusivity Could Carry a Hefty Price Tag.” In it, she quoted sources who are very concerned that reducing the current 12-year exclusivity…
An Optimist’s Take on Funding Options for Small Biotechs
No, that’s not a typo. I’m feeling optimistic about fundraising opportunities for small biotechs. Yes, I know we’re seeing venture firms pull back on an almost weekly basis (Prospect Ventures, Scale Venture Partners, etc.). And yes, I know the NVCA…
Casting Calls for Pfizer: The Movie
In the August 15, 2011, issue of Fortune, the story “Inside Pfizer’s palace coup” provided a detailed account of the ouster of Jeff Kindler, CEO of Pfizer Inc. until December 2010.
Join the Conversation